Current Treatment and Recent Clinical Research in Alzheimer's Disease

被引:63
作者
Neugroschl, Judith [1 ]
Sano, Mary [1 ,2 ]
机构
[1] Mt Sinai Sch Med, New York, NY 10029 USA
[2] James J Peters Vet Affairs Med Ctr, Bronx, NY USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2010年 / 77卷 / 01期
关键词
Alzheimer's disease; amyloid; antioxidant; Dimebon; immunotherapy; receptor for advanced glycation end products; research; secretase; tau; treatment; ESTROGEN REPLACEMENT THERAPY; NERVE GROWTH-FACTOR; TOTAL HOMOCYSTEINE LEVELS; DOUBLE-BLIND; A-BETA; COGNITIVE FUNCTION; GINKGO-BILOBA; MEMORY IMPAIRMENT; CONTROLLED-TRIAL; UNITED-STATES;
D O I
10.1002/msj.20165
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The transition from either epidemiological observation or the bench to rigorously tested clinical trials in patients with Alzheimer's disease is clinical in understanding which treatments are beneficial to patients. The amyloid hypothesis has undergone scrutiny recently, as many trials aimed at reducing and plaque have been completed or are in the testing phase. Examples include modulation of the secretases involved in beta amyloid formation, anti-aggregation agents, and immunotherapeutic trials. Other therapies targeting hyperphosphorylated tau and novel targets such as enhancement mitochondrial function, serotonin receptors, receptor for advanced glycation end products, and nerve growth factor, as well as other strategies, are discussed. A brief review of the current Food and Drug Administration-approved treatments is included. Mt Sinai J Med 77:3-16, 2010. (C) 2010 Mount Sinai School of Medicine
引用
收藏
页码:3 / 16
页数:14
相关论文
共 127 条
[1]   High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial [J].
Aisen, Paul S. ;
Schneider, Lon S. ;
Sano, Mary ;
Diaz-Arrastia, Ramon ;
van Dyck, Christopher H. ;
Weiner, Myron F. ;
Bottiglieri, Teodoro ;
Jin, Shelia ;
Stokes, Karen T. ;
Thomas, Ronald G. ;
Thal, Leon J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (15) :1774-1783
[2]   Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States [J].
Aisen, Paul S. .
ALZHEIMERS & DEMENTIA, 2009, 5 (02) :125-127
[3]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[4]   A randomized controlled trial of prednisone in Alzheimer's disease [J].
Aisen, PS ;
Davis, KL ;
Berg, JD ;
Schafer, K ;
Campbell, K ;
Thomas, RG ;
Weiner, MF ;
Farlow, MR ;
Sano, M ;
Grundman, M ;
Thal, LJ .
NEUROLOGY, 2000, 54 (03) :588-593
[5]  
*ALZF, DRUGS CLIN TRIALS CE
[6]  
*ALZH ASS, 2007, PHYS STUD FIN REP
[7]  
*ALZH RES FOR, FDA DEEMS US ALZH TR
[8]  
*AN COUNC MED WOM, 1933, LANCET, V1, P106
[9]  
[Anonymous], 1976, CHEM OCEANOGRAPHY
[10]   Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways [J].
Atamna, Hani ;
Nguyen, Andy ;
Schultz, Carla ;
Boyle, Kathleen ;
Newberry, Justin ;
Kato, Hiroyuki ;
Ames, Bruce N. .
FASEB JOURNAL, 2008, 22 (03) :703-712